Skip to main content
SpringerLink
Log in

Oral Agents

  • Chapter
Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 109 Accesses

Abstract

As discussed in previous chapters, platelets play a central role in the pathogenesis of thrombosis and acute coronary events. Thus, antiplatelet therapy is a cornerstone of treatment for patients with atherosclerotic coronary artery disease. Despite the effectiveness of intravenous inhibitors of the platelet glycoprotein (GP) IIb/IIIa receptor in patients with acute coronary syndromes or undergoing percutaneous coronary intervention (PCI), little additional benefit is realized beyond the termination of therapy, and 30-d death or myocardial infarction rates remain in the 7–13% range (1,2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein integrin in ischemic heart disease. Circulation 1998;98:2829–2835.

    Article  PubMed  CAS  Google Scholar 

  2. Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/Illa inhibition. J Am Coll Cardiol 2000;36:2028–2035.

    Article  PubMed  CAS  Google Scholar 

  3. Patrono C. Drug therapy: aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287–1294.

    Article  PubMed  CAS  Google Scholar 

  4. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy— I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.

    Article  Google Scholar 

  5. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 1999;83:1147–1151.

    Article  PubMed  CAS  Google Scholar 

  6. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance among patients with cardiovascular disease. Am J Cardiol 2001;88:230–235.

    Article  PubMed  CAS  Google Scholar 

  7. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responders. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397–403.

    Article  PubMed  CAS  Google Scholar 

  8. Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 2000;101:76–80.

    Article  Google Scholar 

  9. Leebeek FWG, Boersma E, Cannon CP, Van de Werf FJJ, Simoons ML. Oral glycoprotein IIB/IIIA receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable? Eur Heart J 2002;23:444–457.

    Article  PubMed  CAS  Google Scholar 

  10. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437–444.

    Article  PubMed  CAS  Google Scholar 

  11. Mousa S, Kapil R, Mu D-X. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/ Illa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler Thromb Vasc Biol 1999; 19:2535–2541.

    Article  PubMed  CAS  Google Scholar 

  12. Kerieakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998;98:1268–1278.

    Article  Google Scholar 

  13. Ferguson JJ, Deewania PC, Kereiakes DJ, et al. Sustained platelet GP IIb/Illa blockade with oral orbofiban: interim pharmacodynamic results of the SOAR study. J Am Coll Cardiol 1998;31:185A (abstract).

    Article  Google Scholar 

  14. Cannon CP, McCabe CH, Borzak, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban in patients after an acute coronary syndrome: results of the TIMI 12 Trial. Circulation 1998;97:340–349.

    Article  PubMed  CAS  Google Scholar 

  15. Akkerhuis KM, Neuhaus KL, Wilcox RG, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhihition with lefradafiban in patients with acute coronary syndromes without ST-elevation. Eur Heart J 200021:2042–2055.

    Google Scholar 

  16. Harrington RA, Armstrong PW, Graffignino C, et al. for the Anti-PLAtelet Useful Dose (APLAUD) Study Investigators. Dose-finding, safety, and tolerability of an oral platelet glycoprotein IIb/lIla inhibitor, lotrafiban, in patients with coronary or cerebral athersclerotic disease. Circulation 2000;102:728–735.

    Article  PubMed  CAS  Google Scholar 

  17. Jennings L, Wise K, Ramsey M, et al. Comparison of platelet aggregation response and receptor occupancy of RPR 109891 administered intravenously in patients with recent acute recent acute coronary syndromes (TIMI 15A). J Am Coll Cardiol 1998;31:353A (abstract).

    Article  Google Scholar 

  18. Langer A, Goodman SG, Reilly TM, et al. Second generation oral IIb/IIIa receptor blockade: phase II experience with roxifiban. J Am Coll Cardiol 2000;35:308A (abstract).

    Article  Google Scholar 

  19. Newby LK, Ohman EM, Christenson RH, et al., for the PARAGON B Investigators. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON B Troponin T Substudy. Circulation 2001;103:2891–2896.

    Article  PubMed  CAS  Google Scholar 

  20. Heeshcen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757–1762.

    Article  Google Scholar 

  21. O’Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000;342:1316–1324.

    Article  PubMed  Google Scholar 

  22. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000;102:149–156.

    Article  PubMed  CAS  Google Scholar 

  23. Newby LK. Long-term oral platelet glycoprotein Hb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the SYMPHONY trial. Am Heart J 1999;138:210–218.

    Article  PubMed  CAS  Google Scholar 

  24. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000;355:337–345.

    Article  Google Scholar 

  25. The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727–1733.

    Article  Google Scholar 

  26. Topol EJ, Easton JD, Amarenco P, et al. Design of the Blockade of the glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial. Am Heart J 2000;139:927–933.

    Article  PubMed  CAS  Google Scholar 

  27. Mould D, Chapelsky M, Alun i J, Swagzdis J, Samuels R, Granett J. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Ther 2001;69: 210–222.

    Article  PubMed  CAS  Google Scholar 

  28. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000;36:1514–1519.

    Article  PubMed  CAS  Google Scholar 

  29. Quinn MJ, Cox D, Foley JB, Fitzgerald DJ. Glycoprotein lIb/IlIa receptor number and occupancy during chronic administration of an oral antagonist. JPET 2000;295:670–676.

    CAS  Google Scholar 

  30. Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999;99:2231–2238.

    Article  PubMed  CAS  Google Scholar 

  31. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-lIla. Cardiovasc Res 2000;45:437–446.

    Article  PubMed  CAS  Google Scholar 

  32. Jennings LK, White MM. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J 1998;135:S179–S183.

    Article  PubMed  CAS  Google Scholar 

  33. Jennings LK, White MM, Mandrell TD. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb/IIIa functional activity. Thromb Haemost 1995; 74:1551–1556.

    PubMed  CAS  Google Scholar 

  34. Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/ IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 2001;104:1374–1379.

    Article  PubMed  CAS  Google Scholar 

  35. Holmes MB, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Am J Cardiol 2000;85:491–493.

    Article  PubMed  CAS  Google Scholar 

  36. Serrano CV, Venturinelli M, Ramires JAF, Cannon CP, Nicolau JC. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil-platelet interactions in patients with acute coronary syndromes. J Am Coll Cardiol 2000;35:343A (abstract).

    Google Scholar 

  37. Adderly SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000;275:5760–5766.

    Article  Google Scholar 

  38. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999;397:534–539.

    Article  PubMed  CAS  Google Scholar 

  39. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. J Am Coll Cardiol 1999;33:634–639.

    Article  PubMed  CAS  Google Scholar 

  40. Hughes S. BRAVO trial stopped: lotrafiban increases mortality. The Heart.org.

    Google Scholar 

  41. Newby LK, Califf RM, White HD, et al. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002;112:647–658.

    Article  PubMed  CAS  Google Scholar 

  42. Chew DP, Bhatt DL, Sapp S, Topo! EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201–206.

    Article  PubMed  CAS  Google Scholar 

  43. The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

    Article  Google Scholar 

Download references

Authors
  1. L. Kristin Newby MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA

    A. Michael Lincoff MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Newby, L.K. (2003). Oral Agents. In: Lincoff, A.M. (eds) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-376-7_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-376-7_17

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-408-1

  • Online ISBN: 978-1-59259-376-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation